News & Insights

Stay Informed With Our Latest Updates

Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.

Insights > Keyword
Insights > Type
Global > Practices
Global > Industries
Insights > Location
Insights > Person
Insights > Date Filter
4369 Results Found

Webcasts September 24, 2026

Webcast: FCA Enforcement in 2026: Key Trends and DOJ Initiatives

Join our lawyers for a recorded webcast as they analyze key developments in False Claims Act enforcement related to healthcare, …

Publications September 16, 2026

Deal Trends — In Focus: Life Sciences

Our partners share insights on the trends shaping dealmaking in the Life Sciences sector—and what to watch in the months ahead.

Client Alert August 31, 2026

How ‘Most Favored Nation’ Regime Affects Biopharma Deals

This article describes the current state-of-play with MFN and key deal drafting considerations. Life sciences dealmaking is running at a …

Article August 27, 2026

Margaux Hall, Branden Berns, and Karen Spindler Have Authored Law360’s “How ‘Most Favored Nation’ Regime Affects Biopharma Deals”

Partners Margaux Hall, Branden Berns, and Karen Spindler have authored Law360’s “How 'Most Favored Nation' Regime Affects Biopharma Deals”

Client Alert August 11, 2026

FDA Proposes Mandatory GRAS Notification for Food Substances, with a Time-Limited Streamlined Path

FDA has proposed converting its voluntary notification program for substances in food that are generally recognized as safe (GRAS) into a mandatory one, with a one-year window for streamlined submissions for food substances already on the market. If the GRAS notification requirement is not met, FDA intends to consider noncompliance as a factor in its prioritization of food substances for post-market review.

Publications August 6, 2026

Biopharma M&A: Mid-Cap Public-Target Market Survey (First-Half 2026)

In the first six months of 2026, acquirers announced 13 qualifying acquisitions of public biopharma targets worth $66.6 billion in upfront consideration.

Publications August 5, 2026

Contingent Value Rights: A Drafting Guide for Biopharma M&A

Contingent value rights have become a defining feature of biopharma M&A, appearing in under 10% of mid-cap public-target deals before 2019 but a quarter to a third of them in every year since 2023.

Client Alert July 30, 2026

False Claims Act 2026 Mid-Year Update

This update summarizes noteworthy enforcement activity from the first six months of 2026. We discuss significant federal policy and state …